Meeting
2021 ASCO Annual Meeting
Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.
Authors
Patrick Joseph O'Shea
Cleveland Clinic, Cleveland, OH
Patrick Joseph O'Shea , Vineeth Tatineni , Yasmeen Rauf , Xuefei Jia , Erin Sennett Murphy , Samuel T. Chao , John H. Suh , David M. Peereboom , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2030)
DOI
10.1200/JCO.2021.39.15_suppl.2030
Abstract #
2030
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
First Author: Enrique Grande
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman